1. Home
  2. TBI vs RANI Comparison

TBI vs RANI Comparison

Compare TBI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrueBlue Inc.

TBI

TrueBlue Inc.

HOLD

Current Price

$4.24

Market Cap

139.9M

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$1.30

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBI
RANI
Founded
1985
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.9M
126.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
TBI
RANI
Price
$4.24
$1.30
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$6.00
$8.60
AVG Volume (30 Days)
252.2K
804.3K
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
61.39
21.05
EPS
N/A
N/A
Revenue
N/A
$1,028,000.00
Revenue This Year
$6.25
$414.59
Revenue Next Year
$3.90
$30.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.44
$0.39
52 Week High
$7.78
$3.87

Technical Indicators

Market Signals
Indicator
TBI
RANI
Relative Strength Index (RSI) 44.41 46.15
Support Level $3.44 $0.46
Resistance Level $6.28 $1.54
Average True Range (ATR) 0.27 0.08
MACD 0.04 0.01
Stochastic Oscillator 60.80 45.24

Price Performance

Historical Comparison
TBI
RANI

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: